Targeting the kidney in acute decompensated heart failure: Conventional diuretics and renal-acting vasodilators

Reviews in Cardiovascular Medicine

Volumn 9, Issue 1, 2008, Pages 39-45

  Martin, Fernando L ^a   Chen, Horng H ^a   Cataliotti, Alessandro ^a   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute decompensated heart failure; Diuretics; Renal function; Renin angiotensin aldosterone system; Vasodilators

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; DIURETIC AGENT; FUROSEMIDE; LOOP DIURETIC AGENT; NESIRITIDE; NITROPRUSSIDE SODIUM; VASODILATOR AGENT;

ACUTE HEART FAILURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIURESIS; GLOMERULUS FILTRATION RATE; HEART PRELOAD; HUMAN; HYPOTENSION; KIDNEY FUNCTION; KIDNEY PERFUSION; LOW DRUG DOSE; NATRIURESIS; NONHUMAN; PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM EXCRETION; SYMPTOMATOLOGY; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; UREMIA;

ACUTE DISEASE; CYCLIC GMP; DIURETICS; FUROSEMIDE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; VASODILATOR AGENTS;

EID: 42249104540     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Braunwald E, Plauth WH Jr, Morrow AG. A method for the detection and quantification of impaired sodium excretion. Circulation. 1965;32:223-230.
2. Fonarow GC, Adams KF Jr, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-580.
3. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.
4. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38:955-962.
5. 1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol. 2003;284:F1115- F1119.
6. Cataliotti A, Boerrigter G, Chen HH, et al. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation. 2002;105:639-644.
7. McCurley JM, Hanlon SU, Wei SK, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol. 2004;44:1301-1307.
8. Garbers DL, Chrisman TD, Wiegen P, et al. Membrane guanylyl cyclase receptors: an update. Trends Endocrinol Metab. 2006;130:229-239.
9. Chen HH, Cataliotti A, Schirger JA, et al. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol. 2005;288:R1093-R1097.
10. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol. 1998;274:F63-F72.
11. Margulies KB, Heublein DM, Perrella MA, Burnett JC Jr. ANF-mediated renal cGMP generation in congestive heart failure. Am J Physiol. 1991;260:F562-F568.
12. Supaporn T, Sandberg SM, Borgeson DD, et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int. 1996;50:1718-1725.
13. Chen HH, Huntley BK, Schirger JA, et al. Maximizing the renal cyclic 3′-5′-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol. 2006;17:2742-2747.
14. Borgeson DD, Stevens TL, Heublein DM, et al. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism. Clin Sci (Lond). 1998;95:195-202.
15. John SW, Veress AT, Honrath U, et al. Blood pressure and fluid-electrolyte balance in mice with reduced or absent ANP. Am J Physiol. 1996;271:R109-R114.
16. Oliver PM, Fox JE, Kim R, et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A. 1997;94:14730-14735.
17. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation. 2003;107:686-689.
18. Elsner D, Muntze A, Kromer EP, Riegger GA. Inhibition of synthesis of endothelium-derived nitric oxide in conscious dogs. Hemodynamic, renal, and hormonal effects. Am J Hypertens. 1992;5:288-291.
19. Shesely EG, Maeda N, Kim HS, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1996;93:13176-13181.
20. Fischmeister R, Castro LR, bi-Gerges A, et al. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res. 2006;99:816-828.
21. Castro LR, Verde I, Cooper DM, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation. 2006;113:2221-2228.
22. Airhart N, Yang YF, Roberts CT Jr, Silberbach M. Atrial natriuretic peptide induces natriuretic peptide receptor-cGMP-dependent protein kinase interaction. J Biol Chem. 2003;278:38693-38698.
23. Martin F, Supaporn T, Chen H, et al. Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure. Am J Physiol Regul Integr Comp Physiol. 2007;293:R1580-R1585.
24. SHEPS Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
25. Misono KS. Atrial natriuretic factor binding to its receptor is dependent on chloride concentration: a possible feedback-control mechanism in renal salt regulation. Circ Res. 2000;86:1135-1139.
26. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136-141.
27. Owan TE, Hodge DO, Herges RM, et al. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. J Card Fail. 2006;12:257-262.
28. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;96:3184-3189.
29. Jensen KT, Eiskjaer H, Carstens J. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Circulation. 1996;94:3184-3189.
30. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
31. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620-1625.
32. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004;109:1680-1685.
33. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
34. Chen HH, Redfield MM, Nordstrom LJ, et al. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail. 2004;10:115-118.
35. Ritter HG, Redfield MM, Burnett JC Jr, Chen HH. Nonhypotensive low-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol. 2006;47:2334-2335.
36. Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37:1221-1227.
37. Mentzer RM Jr, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol. 2007;49:716-726.
38. Chen HH, Sundt TM, Cook DJ, et al. Low dose nesiritide and preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery. Circulation. 2007;116(suppl I):I134-I138.
39. Lisy O, Burnett JC Jr. The design, synthesis and cardiorenal actions of a new chimeric natriuretic peptide CD-NP [abstract]. J Am Coll Cardiol. 2003;41:312A.
40. Lee CYW, Chen HH, Lisy O, et al. A phase I clinical trial on a novel chimeric natriuretic peptide, CD-NP. J Am Coll Cardiol. In press.